거세저항성 전립선암 치료제 개발 동향

Trends in the Development of Castration-resistant Prostate Cancer Treatment

Prostate cancer is one of the most common male cancer. It tends to be known as “mild cancer” due to its high five-year survival rate. However, some patients develop castration-resistant prostate cancer (CRPC) during androgen deprivation therapy (ADT) treatment, with high metastasis and poor prognosis. In addition to conventional ADT treatments, specific treatments are implemented for CRPC. There are four second-generation anti-androgen drugs, taxane chemotherapy, and immunotherapy using vaccines and monoclonal antibodies. This review paper outlines the mechanism of prostate cancer leading to CRPC and reviews the standard treatment of CRPC. It also summarized the trends of anticancer drugs under clinical trials to obtain CRPC as an additional indication.